The acquisition of TriviumVet brings the addition of an innovative new product, Felycin®-CA1, to the PRN® Pharmacal portfolio of products. Felycin is the only FDA conditionally approved drug for the management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM), one of the most common and life-threatening diseases in cats. TriviumVet adds … [Read more...]